- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/102 - PasteurellaHaemophilus
Détention brevets de la classe A61K 39/102
Brevets de cette classe: 372
Historique des publications depuis 10 ans
|
35
|
31
|
30
|
23
|
24
|
23
|
20
|
10
|
14
|
9
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1597 |
40 |
| Intervet Inc. | 920 |
17 |
| Intervet International B.V. | 1334 |
14 |
| Research Institute at Nationwide Children's Hospital | 625 |
9 |
| Engineered Antigens Inc. | 15 |
9 |
| The United States of America, as represented by the Secretary of Agriculture | 1143 |
8 |
| Boehringer Ingelheim Animal Health USA Inc. | 419 |
8 |
| Nationwide Children's Hospital, Inc. | 87 |
6 |
| Sanofi Pasteur SA | 80 |
6 |
| Serum Institute of India Private Limited | 106 |
6 |
| Biotechnology Research and Development Corporation | 13 |
5 |
| Hunter Immunology Limited | 7 |
5 |
| Merial, Inc. | 211 |
5 |
| Cansino Biologics Inc. | 81 |
5 |
| Vaxxinova US, Inc. | 37 |
5 |
| Novartis AG | 10341 |
4 |
| Boehringer Ingelheim Vetmedica, Inc. | 105 |
4 |
| Janssen Pharmaceuticals, Inc. | 440 |
4 |
| Longhorn Vaccines and Diagnostics, LLC | 92 |
4 |
| Qu Biologics Inc. | 25 |
4 |
| Autres propriétaires | 204 |